Your session is about to expire
← Back to Search
SL-1002 for Spasticity (RAISE Trial)
RAISE Trial Summary
This trial is testing a new drug for safety, how it works in the body, and effectiveness for treating spasticity. 32 people will be enrolled and randomly assigned to either the new drug or a placebo. The study will last up to 26 weeks.
- Spasticity
RAISE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRAISE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.RAISE Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many participants is this research project recruiting?
"Affirmative. Per the information on clinicaltrials.gov, this clinical trial is actively seeking participants and has been updated most recently at 9/2/2022 - it was initially posted 4/22/2022 with an aim to include 32 patients from 2 sites in total."
Are there any prerequisites for participating in this research trial?
"This clinical experiment seeks 32 adults aged 18 to 80 who suffer from spasticity of either cortical or spinal origin, that can be managed via chemo denervation. Additional qualifications include: a MAS score for the related limbs and muscles greater than two; BMI between 18.0-29.9 kg/m2 with total body weight over 50kg (male) or 45.5kg (female); hormonal contraceptive use beginning at least four weeks prior to study drug administration; nonpregnant female participants with an intrauterine device in place since 4 weeks before study drugs are administered, male partners using condoms plus spermicides starting"
Is this experiment open to participants older than 25 years of age?
"According to the study's criteria, participants must be 18 years or older and no more than 80 for enrolment."
What dangers, if any, have been identified with the utilization of SL-1002?
"SL-1002 has been rated a 2 on the safety scale, as there have only been Phase 2 trials conducted thus far. Therefore, while some data is available to support its security parameters, no information exists indicating efficacy at this time."
Is the sign-up window for this medical experiment still open?
"Affirmative. The clinical trial is currently in the process of recruiting participants, with a commencement date on April 22nd 2022 and an updated listing posted September 2nd 2022. 32 patients will be sought from two separate medical sites."
Share this study with friends
Copy Link
Messenger